

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date January 21, 2011

Frontier Building, 3601 C Street; Room 890/896

Agenda

Call in: 1-800-315-6338. Use access code 735#.

FINAL

Call to Order – Chair Richard Brodsky, MD

8:00 am

Roll Call

8:05 am

Public Comment - (See guidelines on page 2)

Local Public / Health Practitioners

The Department has developed a new method for class review to better utilize the time of the P&T Committee. Three sets of classes are up for review. Classes shown in **Red** are new classes or classes where new information exists and public testimony will be taken. Classes shown in **Blue** will be reviewed only if new information is received, then public testimony will be taken. For the classes shown in **Green**, no changes have been noted and no public testimony will be taken. New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

Public Comment on Blue/Red Classes	
Discussion & vote on Red Classes	
The Department will review the following red classes as the classes are new or new information exists.	
Review Other Acne Agents -Dapsone	Re-review GLP-1 Receptor Agonist*
Re-Review Immunosuppressants	*Review Topical NSAIDS
The Department proposes no changes to the P&T Committee's clinical recommendation in the following blue classes unless new information is received.	
Re-Review ARB's	Re-review DPP-4 Inhibitor *
Re-Review TZD's	Re-Review Renin Inhibitors
The Department proposes no changes to the P&T Committee's clinical recommendation to the following classes as shown in green .	
Re-Review ACE	Re-Review Alpha Glucosidase Inhibitor
Re-Review Amylin Analogues*	Re-review Androgenic Agents
Re-Review Beta Blockers - Oral	Re-Review Benzoyl Peroxide/Clindamycin Combos
Re-Review Calcium Channel Blocker	Re-Review Biguanides
Re-Review Insulins	Re-Review Glaucoma Agents
Re-Review Metglinides	*Review Topical Anesthetics
Re-Review Topical Immunomodulators	Re-review Topical Retinoids
Re-Review Sulfonylureas	Re-Review Ulcerative Colitis – Oral
*Note: These classes were formerly included in the Incretin Mimetics	
Break as needed – 15 minutes	
Review minutes from November 2010 meeting	
Comments from Committee Members or Chair	
Adjourn	

Future Meeting Dates: April 15, 2011

GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE
January 21, 2011

1. All interested speakers are required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area, prior to the start of the meeting.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of three (3) minutes in total.
3. Only one speaker "slot" will be available per drug class representing a single manufacturer or interest group. Within the allowable three (3) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted First Health prior to the meeting.